Cargando…

Bloodstream Infection due to Piperacillin/Tazobactam Non-Susceptible, Cephalosporin-Susceptible Escherichia coli: A Missed Opportunity for De-Escalation of Therapy

An increasing number of reports describing Escherichia coli isolates with piperacillin/tazobactam resistance, despite retained cephalosporin susceptibility, suggest further emergence of this phenotypic resistance pattern. In this report, a patient with metastatic breast cancer presented to medical c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Carlisle, Leah, Justo, Julie Ann, Al-Hasan, Majdi N.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2018
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6316510/ https://www.ncbi.nlm.nih.gov/pubmed/30513755 http://dx.doi.org/10.3390/antibiotics7040104

Ejemplares similares

Piperacillin/tazobactam-resistant, cephalosporin-susceptible Escherichia coli bloodstream infections are driven by multiple acquisition of resistance across diverse sequence types
por: Edwards, Thomas, et al.
Publicado: (2022)

Epidemiology of Bloodstream Infections Caused by Escherichia coli and Klebsiella pneumoniae That Are Piperacillin-Tazobactam-Nonsusceptible but Ceftriaxone-Susceptible
por: Baker, Thomas M, et al.
Publicado: (2018)

Comparative in vitro activity of piperacillin-tazobactam and temocillin against third-generation cephalosporin-resistant, carbapenem-susceptible Escherichia coli and Klebsiella pneumoniae
por: Kresken, Michael, et al.
Publicado: (2021)

305. Prevalence of Ceftriaxone Susceptible, Piperacillin-tazobactam Non-susceptible Escherichia coli Bacteremia in Patients with Hematologic Malignancy
por: Spitznogle, Sarah L, et al.
Publicado: (2020)

2290. Carbapenem vs. Piperacillin–tazobactam Definitive Therapy for Patients with Bloodstream Infections Due to Ceftriaxone Not Susceptible Escherichia coli or Klebsiella species
por: MacVane, Shawn H, et al.
Publicado: (2019)

Minimal impact of selective susceptibility reporting on the use of piperacillin-tazobactam for Escherichia coli and Klebsiella bacteremia
por: Zahlanie, Yorgo, et al.
Publicado: (2021)

1061. Decreased Utilization of Piperacillin–Tazobactam for Escherichia coli and Klebsiella Bacteremia due to Selective Susceptibility Reporting
por: Zahlanie, Yorgo, et al.
Publicado: (2019)

2407. Emerging Piperacillin/Tazobactam Resistance in Escherichia coli and Klebsiella sp.
por: Suseno, Mira, et al.
Publicado: (2018)

Rapid Detection of Piperacillin-Tazobactam Resistance in Klebsiella pneumoniae and Escherichia coli
por: Ortiz de la Rosa, José Manuel, et al.
Publicado: (2023)

Efflux Pump AcrAB Confers Decreased Susceptibility to Piperacillin–Tazobactam and Ceftolozane–Tazobactam in Tigecycline-Non-Susceptible Klebsiella pneumoniae
por: Li, Junjie, et al.
Publicado: (2020)

A Case of Bacteremia and Meningitis Associated with Piperacillin-Tazobactam Nonsusceptible, Ceftriaxone Susceptible Escherichia coli during Strongyloides Hyperinfection in an Immunocompromised Host
por: Dahal, Santosh, et al.
Publicado: (2017)

Extensive Gene Amplification as a Mechanism for Piperacillin-Tazobactam Resistance in Escherichia coli
por: Schechter, Lisa M., et al.
Publicado: (2018)

Meropenem versus piperacillin-tazobactam for definitive treatment of bloodstream infections due to ceftriaxone non-susceptible Escherichia coli and Klebsiella spp (the MERINO trial): study protocol for a randomised controlled trial
por: Harris, Patrick NA, et al.
Publicado: (2015)

1809. Treatment Outcomes in Piperacillin-tazobactam Non-susceptible (TZP-NS)/Ceftriaxone Susceptible (CRO-S) Infections
por: Dubrovskaya, Yanina, et al.
Publicado: (2022)

Third generation cephalosporins and piperacillin/tazobactam have distinct impacts on the microbiota of critically ill patients
por: Gamage, Hasinika K. A. H., et al.
Publicado: (2021)

Piperacillin/Tazobactam (ZOSYN)
por: Culver, Stephanie M., et al.
Publicado: (1996)

Antimicrobial Susceptibility of E. coli Isolates from Intra-Abdominal Infections in the Asia-Pacific Region: Trends in Ciprofloxacin, Ceftriaxone, Cefepime, and Piperacillin/Tazobactam Susceptibility
por: Tsai, Chia-Hung, et al.
Publicado: (2023)

Mechanisms of Piperacillin/Tazobactam Nephrotoxicity: Piperacillin/Tazobactam-Induced Direct Tubular Damage in Mice
por: Yang, Jihyun, et al.
Publicado: (2023)

Ultrasensitive and rapid identification of ESRI developer- and piperacillin/tazobactam-resistant Escherichia coli by the MALDIpiptaz test
por: Rodríguez Villodres, Angel, et al.
Publicado: (2022)

Piperacillin/tazobactam Induced Myelosuppression
por: Lee, Kirsty Wai Chung, et al.
Publicado: (2009)

Comparable Effectiveness of Cefuroxime and Piperacillin-Tazobactam as Empirical Therapy for Methicillin-Susceptible Staphylococcus aureus Bacteremia
por: Bigseth, Robert Strengen, et al.
Publicado: (2022)

Treatment of Piperacillin-Tazobactam–Nonsusceptible/Ceftriaxone-Susceptible Infections With Carbapenem Versus Carbapenem-Sparing Antimicrobials
por: Cao, John, et al.
Publicado: (2023)

2576. Piperacillin-Tazobactam or Cefepime for Treatment of Third Generation Cephalosporin Resistant Pneumonia in Intensive Care Unit Patients
por: DeLaurentis, Clare, et al.
Publicado: (2023)

Evaluation of Piperacillin/Sulbactam, Piperacillin/Tazobactam and Cefoperazone/Sulbactam Dosages in Gram-Negative Bacterial Bloodstream Infections by Monte Carlo Simulation
por: Wang, Xueting, et al.
Publicado: (2023)

646. Adapting the modified Carbapenem Inactivation Method to assess for possible beta-lactamase mediated resistance in Piperacillin-Tazobactam resistant/ Ceftriaxone susceptible Escherichia. coli and Klebsiella pneumoniae
por: Lawandi, Alexander, et al.
Publicado: (2020)

Early treatment response to piperacillin/tazobactam in patients with bloodstream infections caused by non-ESBL ampicillin/sulbactam-resistant Escherichia coli: a binational cohort study
por: Tobudic, Selma, et al.
Publicado: (2023)

DRESS syndrome induced by piperacillin-tazobactam
por: Sanchez-Gonzalez, Maria-Jose, et al.
Publicado: (2014)

Incidence and impact on clinical outcome of infections with piperacillin/tazobactam resistant Escherichia coli in ICU: A retrospective study
por: Meybeck, Agnès, et al.
Publicado: (2008)

Therapeutic Management of Pseudomonas aeruginosa Bloodstream Infection Non-Susceptible to Carbapenems but Susceptible to “Old” Cephalosporins and/or to Penicillins
por: Zaidenstein, Ronit, et al.
Publicado: (2018)

Determining the in vitro susceptibility of tebipenem, an oral carbapenem, against third-generation cephalosporin-resistant Escherichia coli and Klebsiella pneumoniae isolated from bloodstream infections
por: Ranasinghe, Ama, et al.
Publicado: (2022)

212. Effectiveness of Empirical Piperacillin/tazobactam Compared to Cefepime for Bloodstream Infection Caused by Gram-Negative Bacilli
por: Ho Lee, Young, et al.
Publicado: (2023)

Enterobacter endophthalmitis: Treatment with intravitreal tazobactam- piperacillin
por: Singh, Trehan Hemant, et al.
Publicado: (2007)

Piperacillin-tazobactam-induced hypokalemia and metabolic alkalosis
por: Zaki, Syed Ahmed, et al.
Publicado: (2011)

Piperacillin–tazobactam as alternative to carbapenems for ICU patients
por: Pilmis, Benoit, et al.
Publicado: (2017)

Piperacillin/tazobactam: Eosinophilic-pneumonia: case report
Publicado: (2021)

1555. Risk of Developing Acute Kidney Injury in Patients Receiving Piperacillin–Tazobactam and Vancomycin Compared with Those on Piperacillin–Tazobactam and Telavancin
por: Reilly, Joseph, et al.
Publicado: (2019)

Diminished Susceptibility to Cefoperazone/Sulbactam and Piperacillin/Tazobactam in Enterobacteriaceae Due to Narrow-Spectrum β-Lactamases as Well as Omp Mutation
por: Yang, Fengzhen, et al.
Publicado: (2022)

Piperacillin-Tazobactam Versus Anti-Pseudomonal Cephalosporins and Renal and Neurologic Outcomes in Critically Ill Adults: A Secondary Analysis of the SMART Trial
por: Qian, Edward T., et al.
Publicado: (2023)

Piperacillin-Tazobactam (TZP) Resistance in Escherichia coli Due to Hyperproduction of TEM-1 β-Lactamase Mediated by the Promoter Pa/Pb
por: Zhou, Kaixin, et al.
Publicado: (2019)

Piperacillin/tazobactam resistance in a clinical isolate of Escherichia coli due to IS26-mediated amplification of bla(TEM-1B)
por: Hubbard, Alasdair T. M., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_m3gfdjtca28v6p9d0gahhu3cmo